Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major antibody categories: those to the acetylcholine receptor (AChR ...

This article provides a thorough overview of the pathophysiology and current treatment options for myasthenia gravis, an autoimmune and antibody-mediated neuromuscular disease.

Advances in the Treatment of Myasthenia Gravis Nils Erik Gilhus Disclosures Future Neurology. 2012;7 (6):701-708. Pathogenesis MG patients should always be diagnosed according to disease subgroup.

Thymoma screening is recommended at the onset of myasthenia gravis (MG) or when patients with MG present with clinical deterioration or a progressive increase of anti-acetylcholine receptor antibody.

Thymectomy for Myasthenia Gravis: Predicting Outcomes —A retrospective analysis of patients with acetylcholine receptor antibody (AChR-Ab)-positive generalized myasthenia gravis (MG) who ...

Marla Black Morgan, MD, looks to the future of research in both myasthenia gravis and rare neurological disorders by expanding data collection and identifying areas of potential difference in ...

Immune checkpoint inhibitors (ICIs) may induce overlapping myositis/myasthenia gravis (MG) features, sparking current debate about pathophysiology and management of this emerging disease entity. We ...

In today’s Health Headlines, June is Myasthenia Gravis Awareness Month. What is myasthenia gravis, how is it diagnosed, and what treatments are available?